bromocriptine + melatonin + somatostatin

This is a combination therapy consisting of three active pharmaceutical ingredients—bromocriptine, melatonin, and somatostatin—used as part of the Di Bella Multitherapy (DBM) regimen. The combination is primarily investigated for its potential antitumor effects in advanced cancers and other severe diseases. - **Bromocriptine** is a dopamine D2 receptor agonist that inhibits prolactin secretion and can suppress growth hormone release[7]. - **Melatonin** is an endogenous hormone with antioxidant properties that modulates circadian rhythms and may have antiproliferative effects on tumor cells[5]. - **Somatostatin** is a peptide hormone that inhibits the release of several secondary hormones (including growth hormone) and has antiproliferative actions on certain tumors[5]. The combination has been studied in uncontrolled clinical settings as part of broader regimens (often including retinoids, vitamin D, cyclophosphamide), particularly for late-stage or refractory cancers such as non-small-cell lung cancer, low-grade non-Hodgkin’s lymphoma, osteosarcoma, congenital fibrosarcoma, among others[1][2][3][4][5][6]. The proposed mechanisms include inhibition of tumor cell proliferation via hormonal modulation (dopamine/prolactin axis by bromocriptine; suppression of growth factors by somatostatin; antiangiogenic/antioxidant effects by melatonin)[10].

Other names

Di Bella MultitherapyDi Bella regimenDBM